7,8,9,10,11,12-Hexahydrobenzocyclodecen-5-on | 50590-20-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7,8,9,10,11,12-Hexahydrobenzocyclodecen-5-on
• 英文别名: Benzo-1,2-cyclodecen-1-on-3；7,8,9,10,11,12-hexahydro-6H-benzocyclodecen-5-one；7,8,9,10,11,12-Hexahydro-6H-benzocyclodecen-5-on；Benzocyclodecanone；7,8,9,10,11,12-hexahydro-6H-benzo[10]annulen-5-one
• CAS: 50590-20-0
• 化学式: C₁₄H₁₈O
• 分子量: 202.296
• InChiKey: RKZDYIANGMXFQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7,8,9,10,11,12-Hexahydrobenzocyclodecen-5-on 在 氢氧化钾 、 盐酸羟胺 作用下， 生成 1,3,4,5,6,7,8,9-octahydro-benz[b]azacycloundecyn-2-one
  参考文献：
  名称：

  Huisgen et al., Chemische Berichte, 1957, vol. 90, p. 1958,1965

  摘要：

  DOI：
• 作为产物：
  描述：

  12-(benzenesulfonyl)-7,8,9,10,11,12-hexahydro-6H-benzo[10]annulen-5-one 在 镍 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以95%的产率得到7,8,9,10,11,12-Hexahydrobenzocyclodecen-5-on
  参考文献：
  名称：

  通过将芳烃插入CC中，α-磺酰基环状酮的环扩环反应：轻而易举地进入中型和大型苯并环化的碳环

  摘要：

  研究了将芳烃插入α-磺酰基酮的CC中，这导致使用α-磺酰基环状酮时发生环扩环反应。通过扩环和去磺酰化，以中等收率获得了中型和大型苯环化的环状酮。

  DOI：

  10.1016/j.tetlet.2009.01.001

文献信息

• 5-HT2C receptor agonists and compositions and methods of use
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US10272094B2

  公开（公告）日：2019-04-30

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在一些实施方案中，提供了如本文所定义的式 A 化合物，其可调节 5-HT2C 受体的活性。在一些实施方案中还提供了一些方法，例如，用于体重管理、诱导饱腹感和减少食物摄入量，以及预防和治疗肥胖症、抗精神病药诱导的体重增加、2 型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病态赌博、奖赏缺乏综合征和性成瘾）、强迫症谱系障碍和冲动控制障碍（包括咬指甲和嗜睡）、睡眠障碍（包括失眠、睡眠结构破碎和慢波睡眠紊乱）、尿失禁、精神障碍（包括精神分裂症、神经性厌食症和神经性贪食症）、老年痴呆症、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物诱发的运动障碍）、高血压、血脂异常、非酒精性脂肪肝、肥胖相关性肾病和睡眠呼吸暂停。
• 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US20180214455A1

  公开（公告）日：2018-08-02

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.